How Is The Diabetic Peripheral Neuropathy Market Expected To Grow At 8.9% CAGR Over 2025–2029?
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What Is The Projected Valuation Of The Diabetic Peripheral Neuropathy Market In The Coming Years?
There has been significant growth in the market size of diabetic peripheral neuropathy in the past few years. A rise from $3.51 billion in 2024 to $3.83 billion in 2025, delivering a compound annual growth rate (CAGR) of 9.1%, is projected. Factors such as the upsurge in the elderly population, the increasing occurrence of diabetes, growth in healthcare spending, heightened awareness of diabetes-related complications, and the enhancement of healthcare infrastructure have contributed to the growth witnessed in the historic period.
The market for diabetic peripheral neuropathy is predicted to experience robust growth in the coming years, expanding to $5.39 billion in 2029 with a compound annual growth rate (CAGR) of 8.9%. This projected market development in the forecast period can be associated with the rise in inactive lifestyles, bolstered government efforts and funding, the growing occurrence of neuropathy risk factors, improved precision in diagnostics, and a heightened emphasis on early detection and prevention. Key trends projected for the forecast period encompass progress in diagnostic technologies, advancements in therapeutic options, increased spending on research and development, the introduction of less invasive procedures, and a strengthened focus on combined research and development.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21170&type=smp
What Drivers Are Accelerating Expansion Of The Diabetic Peripheral Neuropathy Market?
The surge in health problems related to obesity is predicted to drive the expansion of the diabetic peripheral neuropathy market. The medical condition known as obesity, characterized by an unhealthy accumulation of body fat, could potentially accelerate the risk of numerous chronic illnesses. This escalation in obesity-related health issues is due to heightened awareness, alterations in lifestyle, and an expanded necessity for prevention and treatment measures, consequently leading to a greater demand in healthcare. Diabetic peripheral neuropathy plays a vital role in the management of obesity, offering key insights into the nerve damage induced by conditions related to obesity, thereby directing the targeted interventions to enhance the overall wellness and life quality of the patient. For instance, the World Health Organization (WHO), a Switzerland-based specialized agency of the United Nations in charge of worldwide public health, reported in March 2024 that in 2022, 43% of individuals aged 18 and over were recorded as overweight, and 16% were struggling with obesity. Additionally, there were 37 million children below the age of 5 who were overweight. Amongst children and adolescents between the ages of 5 to 19 years, over 390 million were overweight, out of which 160 million were diagnosed with obesity. Hence, the surge in obesity-related health problems is fuelling the growth of the diabetic peripheral neuropathy market.
How Is The Global Diabetic Peripheral Neuropathy Market Broken Down By Segment?
The diabetic peripheral neuropathymarket covered in this report is segmented –
1) By Disease: Type 2 Diabetic Peripheral Neuropathy; Type 1 Diabetic Peripheral Neuropathy
2) By Treatment: Pain Management Drugs; Gene Therapies
3) By Therapy: Antidepressants; Anticonvulsants
4) By Patient Population: Adult Patients; Geriatric Patients
Subsegments:
1) By Type 2 Diabetic Peripheral Neuropathy: Sensory Neuropathy; Motor Neuropathy; Autonomic Neuropathy
2) By Type 1 Diabetic Peripheral Neuropathy: Distal Symmetric Neuropathy; Mononeuropathy; Polyradiculopathy
Which Trends Are Likely To Redefine Growth Paths In The Diabetic Peripheral Neuropathy Market?
Prominent players in the diabetic peripheral neuropathy market are emphasizing technological breakthroughs like NaV1.8 pain signal inhibitors, which provide patients with non-opioid alternatives for improved pain control. These inhibitors block sodium channels in sensory neurons to relieve pain. In April 2024, US-based Vertex Pharmaceuticals Incorporated progressed its suzetrigine program by launching a Phase 3 trial for diabetic peripheral neuropathy pain. Suzetrigine, a selective NaV1.8 blocker, has shown encouraging results and earned FDA breakthrough therapy status for DPN pain relief.
Which Firms Are Making The Biggest Impact In The Diabetic Peripheral Neuropathy Market?
Major companies operating in the diabetic peripheral neuropathy market are Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc., Eli Lilly and Company, Astellas Pharma Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Sun Pharmaceutical Industries Limited, Lupin Pharmaceuticals Inc., Chemie Grünenthal GmbH, Alkem Laboratories Limited, Acorda Therapeutics Inc., Mitsubishi Tanabe Pharma Corporation, NeuroMetrix Inc., Regenacy Pharmaceuticals Inc., Helixmith Co. Ltd., Aptinyx Inc., WinSanTor Inc., Sonnet BioTherapeutics Holdings Inc., OLYS Pharma Inc.
Access The Complete Report Here:
Which Geographic Regions Are Creating Strong Demand In The Diabetic Peripheral Neuropathy Market?
North America was the largest region in the diabetic peripheral neuropathy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetic peripheral neuropathy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=21170&type=smp
Browse Through More Reports Similar to the Global Diabetic Peripheral Neuropathy Market 2025, By The Business Research Company
Diabetic Neuropathy Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/diabetic-neuropathy-global-market-report
Chemotherapy Induced Peripheral Neuropathy Treatment Global Market Report 2025
Digital Diabetes Management Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/digital-diabetes-management-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
